Clinical trials: General Anxiety Disorder
Anxiety Disorders
Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder
The primary purpose of this study is to evaluate whether treatment with (SEROQUEL SR) quetiapine fumarate sustained release (SR) for 9 weeks compared to placebo will improve elderly patients with generalised anxiety disorder.
- Trial name
- NCT00389064
- Testing
- Quetiapine XR
- Where
- 43 sites in United States, Estonia and 3 more
- Volunteers
- 450 people
- Sponsor
- AstraZeneca
Anxiety Disorders
Therapeutic Effect of an Herbal Medicine on Anxiety
Phase III, double blind, randomized study, controlled by Valeriana officinalis L for evaluating the efficacy of association of Passiflora incarnata L; Crataegus Oxyacantha L and Salix alba L. in generalized anxiety disorder.
- Trial name
- NCT01178632
- Testing
- Passiflora, Valeriana officinalis
- Where
- Brazil
- Volunteers
- 136 people
- Sponsor
- Millet Roux
Anxiety Disorders
Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325
The purpose of this research study is to determine whether AstraZeneca's drug AZD7325 is safe and effective in the treatment of generalized anxiety disorder.
- Trial name
- NCT00807937
- Testing
- AZD7325, Lorazepam
- Where
- 51 sites in United States
- Volunteers
- 369 people
- Sponsor
- AstraZeneca
Generalized Anxiety Disorder
Safety, Efficacy and Tolerability of Vilazodone in Patients With Generalized Anxiety Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone relative to placebo in the treatment of generalized anxiety disorder (GAD).
- Trial name
- VLZ-MD-06 (NCT01766401)
- Testing
- Vilazadone
- Where
- 30 sites in United States
- Volunteers
- 402 people
- Sponsor
- Forest Laboratories
Generalized Anxiety Disorder
A Study to Asses Safety and Tolerability of ITI-1284 Given Alone or as an Additional Treatment in Participants With Generalized Anxiety Disorder (GAD)
The purpose of this study is to assess how safe ITI-1284 is and how well it can be tolerated in long-term, when given alone or with other medicines, in participants with generalized anxiety disorder (GAD) who have not responded…
- Trial name
- NCT07807865
- Testing
- ITI-1284
- Where
- 3 sites in United States
- Volunteers
- 900 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Major Depressive Disorder, MDD
Operation of Brain Stimulation Equipment Under Remote Viewing Effectiveness Registry
The goal of this observational study is to record and analyze factors putatively affecting the clinical outcomes among patients undergoing transcranial magnetic stimulation (TMS) treatment for major depressive disorder (MDD) or…
- Conditions
- Major Depressive Disorder, MDD, Generalized Anxiety Disorder, GAD
- Trial name
- OBSERVER (NCT06512324)
- Testing
- Ampa One TMS System
- Where
- 2 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- Biomedical Discoveries and Neuroscientific Foundations LLC
General Anxiety Disorder
A Dose-Response Safety Study of ENX-102 in Patients With GAD
This is a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of ENX-102 and determine a dose-response for the effects of ENX-102 in patients with GAD
- Trial name
- NCT06653296
- Testing
- ENX-102
- Where
- 3 sites in United Kingdom
- Volunteers
- 38 people
- Sponsor
- Engrail Therapeutics INC
Generalized Anxiety Disorder
A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)
The purpose of this proof-of-concept trial is to examine the safety, tolerability, and pharmacokinetics (PK), and preliminary clinical efficacy of CYB004 participants with GAD.
- Trial name
- NCT06051721
- Testing
- CYB004, Psychotherapy
- Where
- 6 sites in United States
- Volunteers
- 36 people
- Sponsor
- Cybin IRL Limited
Generalized Anxiety Disorder
Pivotal RCT to Test Safety and Efficacy of Digital Therapeutics 'ANZEILAX' for Managing Generalized Anxiety Disorder
The investigators propose to develop and adapt 'ANZEILAX' smartphone app specifically for individuals with Generalized anxiety disorder.
- Trial name
- NCT06010654
- Testing
- Software as a Medical device
- Where
- South Korea
- Volunteers
- 96 people
- Sponsor
- HAII corp.ltd
Generalized Anxiety Disorder
ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety Disorder
The ENCALM trial is designed to evaluate the efficacy and safety of ENX-102 in patients diagnosed with generalized anxiety disorder (GAD)
- Trial name
- ENCALM (NCT05749055)
- Testing
- ENX-102
- Where
- 32 sites in United States
- Volunteers
- 252 people
- Sponsor
- Engrail Therapeutics INC
Generalized Anxiety Disorder (GAD), Anxiety, Separation
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
This study will evaluate the safety and tolerability of SPD503 in subjects aged 6-17 years with GAD, SAD, or SoP based on treatment emergent adverse events (TEAEs), vital signs and ECGs.
- Conditions
- Generalized Anxiety Disorder (GAD), Anxiety, Separation, Phobia, Social
- Trial name
- NCT01470469
- Testing
- SPD503 (extended-release Guanfacine hydrochloride)
- Where
- 33 sites in United States
- Volunteers
- 83 people
- Sponsor
- Shire
Anxiety Disorders
Study to Evaluate the Safety and Efficacy of GABITRIL Treatment in Adults With Generalized Anxiety Disorder.
A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety and Efficacy of GABITRIL Treatment in Adults with Generalized Anxiety Disorder.
- Trial name
- NCT00214994
- Testing
- Gabitril
- Where
- 93 sites in United States, Canada
- Sponsor
- Cephalon
Healthy Volunteers, Generalized Anxiety Disorder (GAD)
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)
The purpose of this study is to assess the pharmacokinetics, safety, and tolerability following multiple ascending oral doses of ABBV-932 or placebo in healthy adult participants, participants with Generalized Anxiety Disorder…
- Conditions
- Healthy Volunteers, Generalized Anxiety Disorder (GAD), Bipolar Disorder (BPD)
- Trial name
- MAD (NCT06024239)
- Testing
- ABBV-932
- Where
- 3 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- AbbVie
Generalized Anxiety Disorder
A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Participants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Response to GAD Treatment
The purpose of this study is to assess if JNJ-99245354 administered once daily works better to reduce anxiety compared to placebo when given as an additional (adjunctive) therapy in participants with generalized anxiety disorder…
- Trial name
- NCT07856420
- Testing
- JNJ-99245354
- Volunteers
- 705 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Anxiety Disorders
AZD7325 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)
The purpose of this research study is to determine whether AstraZeneca's drug AZD7325 is safe and effective in the treatment of generalized anxiety disorder.
- Trial name
- NCT00808249
- Testing
- AZD7325
- Where
- 52 sites in United States
- Volunteers
- 725 people
- Sponsor
- AstraZeneca
Generalized Anxiety Disorder
Treatment of Patients With Anxiety Disorder (0777-022)
The purpose of the study is to examine the safety and efficacy of MK0777 during treatment for Generalized Anxiety Disorder.
- Trial name
- NCT00539578
- Testing
- MK0777
- Volunteers
- 270 people
- Sponsor
- Merck Sharp & Dohme LLC
Anxiety
Duloxetine vs Placebo in the Treatment of General Anxiety
To see if duloxetine 60 to 120 mg once daily (QD) is better than placebo in the treatment of generalized anxiety disorder (GAD).
- Trial name
- NCT00475969
- Testing
- duloxetine
- Where
- United States
- Volunteers
- 327 people
- Sponsor
- Eli Lilly and Company
Generalized Anxiety Disorder
Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo & Active Control in Generalized Anxiety Disorder
The purpose of this study is to demonstrate that quetiapine SR (SEROQUEL®) is efficacious and safe in the acute treatment of patients with Generalized Anxiety Disorder.
- Trial name
- GOLD (NCT00329446)
- Testing
- Quetiapine Fumarate, Escitalopram oxylate
- Where
- 63 sites in United States
- Volunteers
- 800 people
- Sponsor
- AstraZeneca
Generalized Anxiety Disorder
Safety and Efficacy Evaluation Of Pregabalin (Lyrica) With Patients With Generalized Anxiety Disorder
The purpose of this study is to characterize the safety and efficacy in patients with generalized anxiety disorder after short- (3 months) and long-term (6 months) use of Pregabalin (Lyrica).
- Trial name
- NCT00624780
- Testing
- Pregabalin, Lorazepam
- Where
- 57 sites in Argentina, Austria and 14 more
- Volunteers
- 615 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Anxiety, Generalized Anxiety Disorder
Evaluation of Effects of CBD Products on Anxiety Among U.S. Women
The investigators will conduct a retrospective cohort analysis of a consumer trial conducted by Rae Wellness. The trial took place between October 15, 2020 and December 30, 2020 and involved 1350 U.S.
- Trial name
- NCT05108220
- Testing
- Cannabidiol (CBD)- containing consumer products
- Where
- United States
- Volunteers
- 1,350 people, healthy volunteers welcome
- Sponsor
- Radicle Science